Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexicon

Sanofi reception

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares

Lilly signs real-world digital diabetes deal with Livongo

Will work with the US consumer digital health firm on research collaboration

Sanofi reception

Sanofi and Regeneron ramp up immuno-oncology collaboration

Will put an additional $1bn in investigational candidate cemiplimab

Alexa: find Novo Nordisk voice-activated diabetes tech

Hitlab challenge selects patient education firm Lighthouse for $50,000 funding

Lilly boosts its forthcoming diabetes digital health offering

Strikes diabetes deal with US software and analytics firm Rimidi

Sanofi reception

FDA lifts clinical hold on Sanofi’s haemophilia drug

Phase II and III trials of fitusiran can now resume

Sanofi reception

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The pharma partners begin with a skin cancer filing to the US FDA

Sanofi reception

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The pharma partners begin with a skin cancer filing to the US FDA

Sanofi reception

After some big setbacks, Sanofi talks up its R&D portfolio

Hopes its pipeline of 71 projects delivers strong sales

Sanofi reception

FDA approves Sanofi’s follow-on version of Lilly’s Humalog

French pharma firm hopes Admelog will make a significant commercial impact in 2018

- PMLiVE

Sanofi launches French eHealth laboratory 39BIS

The digital lab will focus on its home market and is based near Paris

- PMLiVE

Novo Nordisk gets FDA nod for once-weekly rival to Lilly’s Trulicity

GLP-1 agonist Ozempic approved in the US for type 2 diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links